It was also reported that an addition of 5-week infusion of GLP-1 to standard therapy in patients with New York Heart Association class III/IV heart failure significantly improved cardiac function, as indicated by left ventricular ejection fraction, maximum myocardial ventilation oxygen consumption, and 6-min walk distance [11]. This evidence concerns the gene GLP1R and heart failure.